Dermata Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $2,929,983 | $8,203,691 |
| Selling, general and administrative (including related party amounts of $645,250 and $0, respectively) | 4,843,615 | 4,309,551 |
| Total operating expenses | 7,773,598 | 12,513,242 |
| Loss from operations | (7,773,598) | (12,513,242) |
| Other income and expenses: | ||
| Interest income | 215,041 | 225,781 |
| Net loss | $(7,558,557) | $(12,287,461) |
| Net loss per share of common stock, basic and diluted | $(8.16) | $(80.32) |
| Weighted-average basic and diluted common shares | 926,192 | 152,974 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.